| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G/A | BOSTON SCIENTIFIC CORP (Filed by) | ||
10-Q | Form 10-Q | ||
8-K | RenovoRx Reports Record Q3 2026 Revenue Exceeding $1 Million and Provides Business Update | ||
RW | Form RW | ||
4 | Macfarlane K. Angela (Reporting) | ||
4 | Spiegel Robert J. (Reporting) | ||
4 | RYAN UNA S (Reporting) | ||
4 | Marton Laurence (Reporting) | ||
4 | VOLL MARK (Reporting) | ||
8-K | RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | ||
10-Q | Form 10-Q | ||
8-K/A | RenovoRx Reports Record Q2 2026 Results and Raises Full-Year Revenue Guidance |
